Maryland Department of Health and Mental Hygiene

Larry Hogan, Governor -

Boyd Rutherford, Lt. Governor -

Van Mitchell, Secretary

Laboratories Administration Robert A. Myers, Ph.D., Director

**DATE:** February 12, 2016

TO:

Medical Laboratory Directors, Local Health Officers, and Health Care Providers

FROM: Robert A. Myers, Ph.D.

Director, Laboratories Administration

Maria Paz Carlos, Ph.D.

Chief, Division of Virology and Immunology, Laboratories Administration

PMC.

RE:

Updated Interim Guidance and Instructions for Submission of Specimens for Suspected Zika

Virus Infection Testing at the Maryland DHMH Laboratory (February 12, 2016)

Effective immediately, the Maryland DHMH Laboratory will begin to perform Zika virus testing using both a reverse transcriptase polymerase chain reaction (RT-PCR) to detect viral RNA in acute specimens and an immunoglobulin (Ig) M enzyme-linked immunosorbent assay (ELISA) to screen specimens for the presence of Zika virus àntibodies.

The MD DHMH Laboratory will also continue to test acute phase specimens approved for Zika virus testing for Dengue and Chikungunya viruses because these mosquito-borne viruses co-circulate in the same geographic areas and the infections can be difficult to distinguish clinically. Only Zika virus ELISA testing will be performed as an initial screen of specimens from pregnant women, who did not have symptoms for Zika virus infection, as per CDC's most recent guidance (Revised Diagnostic Testing for Zika. Chikungunya. and Dengue Viruses in US Public Health Laboratories February 7, 2016; http://www.cdc.gov/zika/pdfs/denvchikvzikv-testing-algorithm.pdf).

An infectious disease consultation by a DHMH or local health department (LHD) epidemiologist is still required to approve specimens for Zika Virus testing at the MD DHMH Laboratory prior to submission. This consultation will determine if the suspect case meets the clinical and travel criteria that would qualify the patient for testing. Contact the DHMH Infectious Disease Epidemiology and Outbreak Response Bureau at (410) 767-6700 (or after hours, at (410) 795-7365) or your LHD to arrange for consultation with an epidemiologist. Prior to contacting the DHMH or LHD epidemiologist, a review of the current interim CDC guidance found in the link below, is highly recommended.

http://phpa.dhmh.maryland.gov/pages/zika.aspx

Please note extensive cross-reactivity in flavivirus serological assays has been documented. Therefore, if specimens are reactive in the Zika IgM ELISA performed at the DHMH Laboratory, an additional paired convalescent serum might be required for submission to the CDC Laboratory for additional plaque reduction neutralization testing (PRNT) to possibly identify the most recently infecting flavivirus.

# **TEST REQUEST FORM**

Complete the DHMH Laboratories Serological Testing Request Form No. 4677 when submitting specimens with prior approval for Zika virus testing to the DHMH Laboratory. Specimens submitted without prior approval from the Health Department will NOT be accepted for testing. Detailed instructions for collecting and submitting acceptable specimens, refer to the attached instructions on the DHMH Serological Testing Request Form No. 4677 Sample Form (Travel-Associated Zika Viral Infections Instructions for Specimen Submission February 12, 2016) or go to the MD DHMH Laboratories website (http://dhmh.maryland.gov/laboratories). Please ensure that all required core demographic and contact information are completed. In addition, please provide the following information to facilitate testing. Failure to include the additional clinical and epidemiological information might result in delays processing of specimens for testing.

a. Name of Health Department Person Approving Testing: Please record on the requisition the name of the DHMH or local health department person approving the testing.

b. Clinical Illness/Compatible clinical presentation: e.g., rash, acute onset fever, conjunctivitis, arthralgia

c. Pertinent travel history: Recent travel to a region where local transmission of Zika virus has been documented (an updated list is available at http://www.cdc.gov/zika/geo/index.html)

d. History of any previous flavivirus infection: e.g., West Nile virus (WNV), dengue virus e. Acute illness on-set date: contemporaneous with the travel exposures in areas of ongoing transmission (illness on-set date ≤14 days after exposure

f. Immunization history: Yellow fever (YF), Japanese encephalitis (JE), or Tick-borne encephalitis (TE) vaccines

## **SPECIMEN TYPES**

### Blood:

For antibody testing (ELISA IgM), 6-10 ml whole blood (red-top tube or serum separator tube) or 3-5 ml sera are acceptable. ELISA IgM testing will be performed on specimens collected ≥4 days after the on-set of illness.

For molecular testing (RT-PCR), in addition to serum (or whole blood), collect 6-10 whole blood in an EDTA purpletop tube or 3-5 ml plasma. Do NOT submit heparinized plasma (green-topped tubes). Heparin will inhibit PCR reactions. RT-PCR testing will be performed on acceptable blood specimens collected within 7 days of the onset of illness.

An additional convalescent specimen for IgM testing could be required to rule-out infections if the acute phase specimen is negative by both PCR and IgM testing after consultation with the health department. Convalescent serum might also be required for additional PRNT testing.

Properly package and transport to the lab on cold packs with completed DHMH Laboratories Serological Testing Request Form No. 4677 (see attached). (Keep specimens refrigerated until transported).

If more than 72 hours will pass before transporting the specimen to MD DHMH Laboratories, serum and plasma should be separated from whole blood and frozen. The serum and plasma should then be shipped frozen.

# **Urine:**

It has been reported in the scientific literature that Zika virus RNA might persist longer in urine than in serum or plasma during the acute phase of the infection. According the MD DHMH Laboratory will accept urine collected within 21 days from onset of illness for RT-PCR testing. Urine specimens must be submitted with whole blood/serum and EDTA whole blood/plasma specimens collected on the same date. Urine specimens received without an accompanying serum and plasma specimens will not be tested. The results of urine testing will be reported for surveillance purposes in conjunction with the Zika RT-PCR results for a serum testing. If Zika virus RNA is only detected in the urine, follow-up Zika antibody testing of serum will be required to confirm seroconversion.

Collect 10-20 ml of urine in leak proof sterile plastic container without preservatives (e.g. urine cup). Label the container with the patient identifiers and the date of collection. Properly seal the container to prevent leaking and place the urine container in a separate sealable plastic bag. Submit the urine along with the serum specimen (see above) collected on the same date and transport to the lab on cold packs with completed DHMH Laboratories Serological Testing Request Form No. 4677 (see attached). (Keep specimens refrigerated until transported). Do not freeze the urine sample.

# **Other Specimen Types**:

Detailed instructions on how to submit other specimen types (including amniotic fluid, cord blood, cerebrospinal fluid (CSF) and tissues) for Zika, dengue, chikungunya and other arboviral tests, contact the MD DHMH Laboratories at (443) 681-3923 or (443) 681-3937 during normal business hours from 8:00 a.m. - 4:30 p.m., Monday through Friday.

# SHIPPING

Specimens collected from individuals for Zika virus testing may be transferred within the U.S. as Category B Biological substances in accordance with Department of Transportation (DoT)Hazardous Materials Regulations (49 CFR Part 171-180). Guidance for packaging samples in accordance with Category B Biological substance requirements can be found in the CDC/NIH Publication Biosafety in Microbiological and Biomedical Laboratories, 5th edition. Additional information on the DoT Hazardous Materials Transport Regulations can be found at https://www.transportation.gov/pipelines-hazmat. Appropriately packaged specimens can be directly shipped via a public carrier to the MD DHMH Laboratory at the following address:

Marvland DHMH Laboratories Administration ATT: Arboviral Laboratory 1770 Ashland Avenue Baltimore, MD 21205 (443) 681-3923 or (443) 681-3937

Alternatively, contact your LHD for other available shipping arrangements to have specimens forwarded to the MD DHMH Laboratory.

Clinical laboratories currently performing chikungunya, dengue, or in the future plan to conduct Zika virus testing, are reminded to report cases of infections and submit clinical materials (i.e. serum, CSF, etc.) from these cases to the MD DHMH Laboratories as required by statute (Annotated Code of Maryland Health-General Article, §§18-201, 18-202, and 18-205, and Code of Maryland Regulations 10.06.01.03C: #9 Arboviral Infections).

Encl:

Updated Travel-Associated Zika Viral Infectious Instructions for Specimen Submission (February 12, 2016) DHMH Laboratories Serological Testing Request Form No. 4677

cc: Dr. Howard Haft

Dr. David Blyth

Dr. Lucy Wilson

Dr. Richard Brooks

Dr. Katherine Feldman

# Instructions for Specimen Submissions February 12, 2016 Updated Travel-Associated Zika Viral Infections

person requesting the test. Must complete submitter information &include the name of the authorized

Travel-Associated Panel, for plasma/whole blood blood (ELISA), and "P" EDTA un-clotted (PCR) Serum/whole clotted Request Arbovirus indicate "S" for

travel history (locations and dates), symptoms, vaccination history, & Complete patient's mmune status.

4:30PM, Monday.-Friday. during normal business For questions on Zika hours from 8:00AM -Virus testing, please (443)681-3923/3937 contact the lab at:

Laboratories Administration MD DHMH 1770 Ashland Ave. • Baltimore, MD 21205 443-681-3800 http://dhmh.maryland.gov/laboratories/Robert A. Myers, Ph.D., Director

STATE LAB Use Only

SEROLOGICAL TESTING

Testing Form. Separate serum & plasma then freeze if held >72

Transport to the lab on cold packs w/ completed Serological

collect 6-10 whole blood in an EDTA purple-top tube or 3-5 ml

For RT-PCR testing, in addition to serum (or whole blood)

serum separator tube) or 3-5 ml sera are acceptable.

plasma. Do NOT submit heparinized plasma (green-topped

tubes). Heparin will inhibit PCR reactions.

For ELISA IgM testing, 6-10 ml whole blood (red-top tube or

leak proof sterile plastic container w/o preservative (urine cup).

Label urine cup with patient identifiers & date of collection.

If you are also submitting URINE, collect 10-20ml of urine in

hours, & transport to the lab frozen.

Submit urine w/ whole blood/serum. Urine ALONE will NOT be

accepted

Submitter Lab # ent SS# (last 4 digits) Outbreak # DEH DEPOMITY/PNONODOSTDOTBOCDOR Zip Code County Fax# **Jealth Care Provider** TYPE OR PRINT REQUIRED INFORMATIC

the specimen container & match exactly Patient's first & last names must be on to the lab slip. Collection date & onset date of symptoms ields must be completed.

Urine ALONE will NOT be accepted. clotted blood (ELISA), and "P" for ndicate "S" for Serum/whole Request CDC/Other Test(s), plasma/whole blood EDTA f you are also submitting specimen, indicate "U" un-clotted (PCR)

You MUST write both "Zika Virus" to request testing & the name of the DHMH/LHD Epidemiologist.

nsfusion? (last 4 months)

□ yes □ no RESTRICTED TEST
Pre-Approved Submitters Only
Submit a separate specimen for HIV
Instructions go to:
http://dhmh.maryland.gov/laboratorles/ □ Negative Specimen transported on cold packs SPECIMEN SOURCE CODE:
PLACE CODE IN BOX NEXT TO TEST
B Blood (5 ml) Name of mother of "at risk" baby: Guardian's name if patient is a Father of baby screen? | yes Serum (1 ml per test) Urine Rapid Test: 

Reactive Cerebrospinal Fluid Lavender Top Tube Hemoglobin Disorders ☐ 1st ☐ 2nd ☐ 3rd State Lab Number: ☐ 1st ☐ 2nd ☐ 3rd State Lab Number: Country of Origin □am □pm "Vaccination History: SSF Prior arrangements have been made with the following DHMH Labs Administration employee: \*Rabies (RFFIT) (\*List vaccination dates above) Syphilis - Previously treated? 

yes 

no Approved by: #### Rocky Mountain Spotted Fever (RMSF) Please Note Vaccination History above\* (Rubeola), Mumps, Rubella, Varicella \*Rubeola (Measles) Immunity Screen Zika Virus Herpes Simplex Virus (HSV) Type (Chickenpox) IgG Ab only] MMRV Immunity Screen: Varicella Immunity Screen "Mumps Immunity Screen **■ SPECIMEN SOURCE CODE** VDRL (CSF only) Add'I Specimen Codes Legionella Collected Hepatitis A Screen (IgM Ab only, acute infection) Arbovirus Endemic Panel (WNV. EEE, SLE, LAG SYMPTOMS: Theadache Clever Cstiff neck
Cattered mental state Tmuscle weakness Crash
Cother Mandatory: Onset Date, Collection Date, and Travel History Required information, check all that apply: DIAGNOSIS: 

DASeptic Meningitis 

Encephalitis rious Test Done? □ no □ yes Name IMMUNIZATIONS: Yellow fever? ☐ yes ☐no Flavivirus? ☐ yes ☐no □ yes □no Call lab (443-681-3889) prior to submitting Arbovirus Travel-Associated Panel (Chikungunya, Dengue) Arbovirus Panels (Serum or CSF) Based on information provided PCR and/or immunological assays will be performed. Hepatitis B Screen (HBs antigen only) \*Hepatitis B Panel: (HBsAg, HBsAb) RAVEL HISTORY (dates and places) \*Hepatitis B post vaccine (HBsAb)
Hepatitis C screen (HCV Ab only)
>HMH 4677 Revised 08/15 Prenatal patient? 

yes 

no ILLNESS FATAL? Dyes Dno Chlamydia (group antigen IgG) MMUNOCOMPROMISED? Epstein-Barr Virus (EBV) Cytomegalovirus (CMV) Cryptococcal (antigen)

STATE LAB
Use Only

# **Laboratories Administration MD DHMH**

1770 Ashland Ave. • Baltimore, MD 21205
443-681-3800 http://dhmh.maryland.gov/laboratories/
Robert A. Myers, Ph.D., Director



# **SEROLOGICAL TESTING**

	☐ EH ☐ FP ☐ MTY/PN ☐ NOD ☐ STD ☐ TB ☐ CD ☐ COR									PERMITTED AND AND AND AND AND AND AND AND AND AN		
Z S	Health Care Provider				Patient SS# (last 4 digits):							
OF III	Address				Last Name				free land	□ SR □ JR □ Other		
SMA	City County				First Name					M.I.		
요필	State Zip Code				Date of Birth (mm/dd/yyyy) / /							
NE	Contact Name:				Address							
REL	Phone# Fax#				City	City County						
DO NO	Test Request Authorized by:				State					Zip Code		
RE S.I.S	Sex:				M Ethnicity: Hispanic or Latino Origin? ☐ yes ☐ no							
ABE		☐ Black/African American ☐ Native Hawaiian/other Pacific Islander ☐ White										
S PR						tbreak # Submitter Lab #						
TYPE OR PRINT REQUIRED INFORMATION OR PLACE LABELS ON ALL THREE COPIES	Date Collected:											
YPE		Date □ 1st □ 2nd □ 3rd S										
-0						Date   1st   2nd   3rd				State Lab Number:		
					□ Clinical Illness/Sympto							
I CDE												
SPECIMEN SOURCE CODE				SPECIMEN SOURCE CODE						PECIMEN SOURCE CODE		
Man	Arbovirus Panels (Seri datory: Onset Date, Collection Da	listory	Herpes Simplex Virus (HSV) Types 1&2					₩ L/	♣ LAVENDER TOP TUBE REQUIRED			
				Legionella						Hemoglobin Disorders		
	Arbovirus Endemic Panel (WNV, EEE, SLE, LAC) Arbovirus Travel-Associated Panel				Leptospira				the gate in	Blood transfusion? (last 4 months)  ☐ yes ☐ no		
(Chikungunya, Dengue)				Lyme Disease						Prenatal screen? □ yes □ no		
Bas	sed on information provided F	est a su <del>pre</del>	*MMRV Immunity Screen: [Measles				Hydron.	Father of baby screen? ☐ yes ☐ no				
immunological assays will be performed.  Required information, check all that apply: DIAGNOSIS: □Aseptic Meningitis □Encephalitis □other □  SYMPTOMS: □headache □fever □stiff neck □altered mental state □muscle weakness □rash □other □  ILLNESS FATAL? □ yes □no  TRAVEL HISTORY (dates and places)				(Rubeola), <b>M</b> umps, <b>R</b> ubella, <b>V</b> aricella (Chickenpox) IgG Ab only]						Guardian's name if patient is a minor: Name of mother of "at risk" baby: ————————————————————————————————————		
									-			
				Mononucleosis - Infectious								
				*Mumps Immunity Screen								
				Mycoplasma								
				Rocky Mountain Spotted Fever (RMSF)						RESTRICTED TEST Pre-Approved Submitters Only Submit a separate specimen for HIV Instructions go to: http://dhmh.maryland.gov/laboratories/		
				*Rabies (RFFIT) (*List vaccination dates above)					) Sı			
				*Rubella Immunity Screen					http			
				*Rubeola (Measles) Immunity Screen					пщ			
IMMUNIZATIONS: Yellow fever? ☐ yes ☐ no Flavivirus? ☐ yes ☐ no IMMUNOCOMPROMISED? ☐ yes ☐ no				Schistosoma						Country of Origin Rapid Test:   Reactive  Negative		
				Strongyloides					Cour			
				Syphilis - Previously treated? ☐ yes ☐ no					. 1			
	and the substitute of the subs	<u> Sakadha e kabatatan ka</u>			Toxoplasma				Date:			
	Aspergillus			Tularemia						Specimen stored refrigerated (2°-8°c) after collection. ☐ yes ☐ no		
Chlamydia (group antigen IgG)				Varicella Immunity Screen								
	Cryptococcal (antigen)				VDRL (CSF only)					Specimen transported on cold packs		
	Cytomegalovirus (CMV)			CDC/Oth						□ yes □ no		
Ehrlichia Epstein-Barr Virus (EBV)				dd'l Specime	n Codes		-	- A 13 - A	And the second second	SPECIMEN SOURCE CODE: PLACE CODE IN BOX NEXT TO TEST		
				Prior ar	rangeme	nts have	been	made with th	e			
Hepatitis A Screen (IgM Ab only, acute infection)  Call lab (443-681-3889) prior to submitting				following DHMH Labs Administration					B Blood (5 ml) CSF Cerebrospinal Fluid L Lavender Top Tube			
				employee:								_
Hepatitis B Screen (HBs antigen only)									- P			
Prenatal patient? ☐ yes ☐ no									s			
*Hepatitis B Panel: (HBsAg, HBsAb)									UR			
*Hepatitis B post vaccine (HBsAb)									-			
Hepatitis C screen (HCV Ab only)				Please Note Vaccination History above*								
<b>DHMH 467</b>	7 Revised 08/15									THE RESERVE OF THE PERSON OF T		